Suchergebnisse - "Kelley, Robin Kate"

PubPharm (45)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

enthalten in: Hepatology (Baltimore, Md.) | 2024

von Hassan, M. | Li, D. | Han, Y. | +50

3

Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma

enthalten in: Gastroenterology & hepatology | 2024

von Kelley, R.

4

Author Correction : Hepatocellular carcinoma

enthalten in: Nature reviews. Disease primers | 2024

von Llovet, J. | Kelley, R. | Villanueva, A. | +7

ErratumFor: Nat Rev Dis Primers. 2021 Jan 21;7(1):6. - PMID 33479224

5

Plain language summary of the HIMALAYA study : tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

enthalten in: Future oncology (London, England) | 2023

von Abou-Alfa, G. | Lau, G. | Kudo, M. | +27

6

Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

enthalten in: Clinical pharmacology and therapeutics | 2023

von Song, X. | Kelley, R. | Green, M. | +10

7

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

enthalten in: Journal of the National Cancer Institute | 2023

von Spencer, K. | Pappas, L. | Baiev, I. | +27

8

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

enthalten in: Cell reports. Medicine | 2023

von Budhu, A. | Pehrsson, E. | He, A. | +28

9

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Kelley, R. | Ueno, M. | Yoo, C. | +119

CommentIn: Lancet. 2023 Jun 3;401(10391):1826-1827. - PMID 37075782

10

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Song, X. | Kelley, R. | Khan, A. | +12

1
2
3
4
5
Nächster »
[5]